BACKGROUND: Although gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) exhibit widely divergent behavior, limited biologic information (apart from Ki-67) is available to characterize malignancy. Therefore, the identification of alternative biomarkers is a key unmet need. Given the role of internexin alpha (INA) in neuronal development, the authors assessed its function in neuroendocrine cell systems and the clinical implications of its expression as a GEP-NEN biomarker. METHODS: Functional assays were undertaken to investigate the mechanistic role of INA in the pancreatic BON cell line. Expression levels of INA were investigated in 50 pancreatic NENs (43 primaries, 7 metastases), 43 small intestinal NENs (25 primaries, 18 metastases), normal pancreas (n = 10), small intestinal mucosa (n = 16), normal enterochromaffin (EC) cells (n = 9), mouse xenografts (n = 4) and NEN cell lines (n = 6) using quantitative polymerase chain reaction, Western blot, and immunostaining analyses. RESULTS: In BON cells, decreased levels of INA messenger RNA and protein were associated with the inhibition of both proliferation and mitogen-activated protein kinase (MAPK) signaling. INA was not expressed in normal neuroendocrine cells but was overexpressed (from 2-fold to 42-fold) in NEN cell lines and murine xenografts. In pancreatic NENs, INA was overexpressed compared with pancreatic adenocarcinomas and normal pancreas (27-fold [P = .0001], and 9-fold [P = .02], respectively). INA transcripts were correlated positively with Ki-67 (correlation coefficient [r] = 0.5; P < .0001) and chromogranin A (r = 0.59; P < .0001). INA distinguished between primary tumors and metastases (P = .02), and its expression was correlated with tumor size, infiltration, and grade (P < .05). CONCLUSIONS: INA is a novel NEN biomarker, and its expression was associated with MAPK signaling and proliferation. In clinical samples, elevated INA was correlated with Ki-67 and identified malignancy. INA may provide additional biologic information relevant to delineation of both pancreatic NEN tumor phenotypes and clinical behavior.
BACKGROUND: Although gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) exhibit widely divergent behavior, limited biologic information (apart from Ki-67) is available to characterize malignancy. Therefore, the identification of alternative biomarkers is a key unmet need. Given the role of internexin alpha (INA) in neuronal development, the authors assessed its function in neuroendocrine cell systems and the clinical implications of its expression as a GEP-NEN biomarker. METHODS: Functional assays were undertaken to investigate the mechanistic role of INA in the pancreatic BON cell line. Expression levels of INA were investigated in 50 pancreatic NENs (43 primaries, 7 metastases), 43 small intestinal NENs (25 primaries, 18 metastases), normal pancreas (n = 10), small intestinal mucosa (n = 16), normal enterochromaffin (EC) cells (n = 9), mouse xenografts (n = 4) and NEN cell lines (n = 6) using quantitative polymerase chain reaction, Western blot, and immunostaining analyses. RESULTS: In BON cells, decreased levels of INA messenger RNA and protein were associated with the inhibition of both proliferation and mitogen-activated protein kinase (MAPK) signaling. INA was not expressed in normal neuroendocrine cells but was overexpressed (from 2-fold to 42-fold) in NEN cell lines and murine xenografts. In pancreatic NENs, INA was overexpressed compared with pancreatic adenocarcinomas and normal pancreas (27-fold [P = .0001], and 9-fold [P = .02], respectively). INA transcripts were correlated positively with Ki-67 (correlation coefficient [r] = 0.5; P < .0001) and chromogranin A (r = 0.59; P < .0001). INA distinguished between primary tumors and metastases (P = .02), and its expression was correlated with tumor size, infiltration, and grade (P < .05). CONCLUSIONS:INA is a novel NEN biomarker, and its expression was associated with MAPK signaling and proliferation. In clinical samples, elevated INA was correlated with Ki-67 and identified malignancy. INA may provide additional biologic information relevant to delineation of both pancreatic NEN tumor phenotypes and clinical behavior.
Authors: G Rindi; G Klöppel; A Couvelard; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann Journal: Virchows Arch Date: 2007-08-03 Impact factor: 4.064
Authors: Stuart A C McDonald; Laura C Greaves; Lydia Gutierrez-Gonzalez; Manuel Rodriguez-Justo; Maesha Deheragoda; Simon J Leedham; Robert W Taylor; Chung Yin Lee; Sean L Preston; Matthew Lovell; Toby Hunt; George Elia; Dahmane Oukrif; Rebecca Harrison; Marco R Novelli; Ian Mitchell; David L Stoker; Douglass M Turnbull; Janusz A Z Jankowski; Nicholas A Wright Journal: Gastroenterology Date: 2007-11-28 Impact factor: 22.682
Authors: Mark Kidd; Irvin M Modlin; Shrikant M Mane; Robert L Camp; Geeta Eick; Igor Latich Journal: Ann Surg Oncol Date: 2006-01-20 Impact factor: 5.344
Authors: Irvin M Modlin; Steven F Moss; Daniel C Chung; Robert T Jensen; Elizabeth Snyderwine Journal: J Natl Cancer Inst Date: 2008-09-09 Impact factor: 13.506
Authors: Mark Kidd; Irvin M Modlin; Roswitha Pfragner; Geeta N Eick; Manish C Champaneria; Anthony K Chan; Robert L Camp; Shrikant M Mane Journal: Cancer Date: 2007-06-15 Impact factor: 6.860
Authors: Irvin M Modlin; Kjell Oberg; Daniel C Chung; Robert T Jensen; Wouter W de Herder; Rajesh V Thakker; Martyn Caplin; Gianfranco Delle Fave; Greg A Kaltsas; Eric P Krenning; Steven F Moss; Ola Nilsson; Guido Rindi; Ramon Salazar; Philippe Ruszniewski; Anders Sundin Journal: Lancet Oncol Date: 2008-01 Impact factor: 41.316
Authors: François Ducray; Ahmed Idbaih; Aurélien de Reyniès; Ivan Bièche; Joëlle Thillet; Karima Mokhtari; Séverine Lair; Yannick Marie; Sophie Paris; Michel Vidaud; Khê Hoang-Xuan; Olivier Delattre; Jean-Yves Delattre; Marc Sanson Journal: Mol Cancer Date: 2008-05-20 Impact factor: 27.401
Authors: Simon Schimmack; Andrew Taylor; Ben Lawrence; Hubertus Schmitz-Winnenthal; Lars Fischer; Markus W Büchler; Irvin M Modlin; Mark Kidd; Laura H Tang Journal: Tumour Biol Date: 2014-09-30
Authors: Lei Cai; Theodoros Michelakos; Vikram Deshpande; Kshitij S Arora; Teppei Yamada; David T Ting; Marty S Taylor; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone Journal: Clin Cancer Res Date: 2019-01-22 Impact factor: 12.531
Authors: D Schult; A Hölsken; M Buchfelder; S-M Schlaffer; S Siegel; I Kreitschmann-Andermahr; R Fahlbusch; R Buslei Journal: Pituitary Date: 2015-08 Impact factor: 4.107
Authors: Liping He; Steeve Boulant; Megan Stanifer; Cuncai Guo; Anna Nießen; Mingyi Chen; Klaus Felix; Frank Bergmann; Oliver Strobel; Simon Schimmack Journal: Cancer Sci Date: 2022-03-08 Impact factor: 6.518
Authors: Francesco Giovinazzo; Simon Schimmack; Bernhard Svejda; Daniele Alaimo; Roswitha Pfragner; Irvin Modlin; Mark Kidd Journal: PLoS One Date: 2013-11-19 Impact factor: 3.240
Authors: Simon Schimmack; Andrew Taylor; Ben Lawrence; Daniele Alaimo; Hubertus Schmitz-Winnenthal; Markus W Büchler; Irvin M Modlin; Mark Kidd Journal: Epigenetics Chromatin Date: 2014-07-21 Impact factor: 4.954